Mesoblast (MEOBF) Beginning Cash Balance (2014 - 2026)
Mesoblast's (MEOBF) quarterly Beginning Cash Balance came in at $161.6 million in Q2 2026, up 156.59% year-over-year from $63.0 million in Q2 2025, and little changed quarter-over-quarter from $161.6 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Beginning Cash Balance (2014 - 2026) Analysis & Trends
Mesoblast has disclosed Beginning Cash Balance across 13 years of filings, most recently posting $161.6 million for Q2 2026.
- In Q2 2026, Beginning Cash Balance rose 156.59% year-over-year to $161.6 million; the TTM figure through Jun 2026 stood at $161.6 million (up 156.59% YoY), while the FY2026 annual figure was $161.6 million, up 156.59% from the prior year.
- Beginning Cash Balance came in at $161.6 million for Q2 2026 at Mesoblast, roughly flat from $161.6 million in the prior quarter.
- In the past five years, Beginning Cash Balance ranged from a high of $161.6 million in Q4 2025 to a low of $60.4 million in Q4 2022.
- Average Beginning Cash Balance over 5 years is $95.2 million, with a median of $71.3 million recorded in 2023.
- Year-over-year, Beginning Cash Balance plunged 55.84% in 2022 and jumped 156.59% in 2025.
- Over 5 years, Beginning Cash Balance stood at $60.4 million in 2022, then advanced by 17.98% to $71.3 million in 2023, then decreased by 11.72% to $63.0 million in 2024, then jumped by 156.59% to $161.6 million in 2025, then changed by 0.0% to $161.6 million in 2026.
- Per Business Quant data, the three most recent Beginning Cash Balance figures were $161.6 million in Q2 2026, $161.6 million in Q4 2025, and $63.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 161.55 Mn |
| Dec 31, 2025 | 161.55 Mn |
| Jun 30, 2025 | 62.96 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Jun 30, 2024 | 71.32 Mn |
| Dec 31, 2023 | 71.32 Mn |
| Jun 30, 2023 | 60.45 Mn |
| Mar 31, 2023 | 60.45 Mn |
| Dec 31, 2022 | 60.45 Mn |
| Jun 30, 2022 | 136.88 Mn |
| Mar 31, 2022 | 136.88 Mn |
| Dec 31, 2021 | 136.88 Mn |
| Sep 30, 2021 | 136.88 Mn |
| Jun 30, 2021 | 129.33 Mn |
| Mar 31, 2021 | 129.33 Mn |
| Dec 31, 2020 | 129.33 Mn |
| Sep 30, 2020 | 129.33 Mn |
| Jun 30, 2020 | 50.43 Mn |
| Mar 31, 2020 | 50.43 Mn |
| Dec 31, 2019 | 50.43 Mn |